Tsingke Biotech highlighted its latest accelerated protein and antibody services at PEGS Europe 2025. The Chinese biotechnology company announced that its services can generate proteins in as little as three days and produce antibodies within seven days, offering a potential step-change in speed for biopharma developers aiming to shorten drug discovery timelines worldwide.

The company combines advanced gene synthesis, automated expression, and purification technologies to deliver rapid protein production. The company supports six expression systems—including E. coli, Bacillus subtilis, yeast, insect, mammalian, and cell-free systems—allowing simple proteins to be produced in three days via cell-free methods, while complex proteins and antibodies are ready in seven to 14 days. According to Tsingke, overall protein expression success reaches 95 percent.

Traditional hybridoma-based antibody development can take one to two months. Tsingke's Single-B Cell Antibody Discovery Service preserves natural VH/VL pairing and generates high-affinity antibodies (10??–10?¹² M), utilising FACS technology. The service is engineered for efficiency, delivering full, comprehensive results in a remarkable timeframe of just eight to 10 weeks. Furthermore, the supported formats encompass a broad spectrum of therapeutic antibodies sourced from both mouse and rabbit models, ensuring versatility for critical research and development needs.

In addition, for antibody production, Tsingke uses Expi293 and CHO-K1 systems, achieving milligram-scale yields in seven days and gram-scale yields in 14 days, with average production exceeding 300 mg/L. A broad range of antibody formats, including VHH-His and VHH-Fc, are available.

Nan Zhang, Global Marketing Manager, Tsingke Biotec, said, "PEGS is a key event for protein and antibody engineering. Our service's combination of speed, customisation, and quality is designed to help the biopharma industry meet the growing demand for faster drug development."